Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director · President and CEO | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
PMV Pharmaceuticals, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2036-03-05 | Direct | 744,960 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 744,960 · Balance 744,960 F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2021 Filed Jun 4, 2021 19:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 10,000 | $0.53 | $5,300.00 |
DisclosureSEC source: 0001209191-21-038419 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed Jun 8, 2021 19:08 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 134,584 | $0.00 Strike: $28.33 | $0.00 |
DisclosureSEC source: 0001209191-21-039028 · doc4.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,584 Underlying: Common Stock · 134,584 shares Expires 2031-05-11 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Read SEC document |
| March 09, 2021 Filed Mar 9, 2022 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017591 · doc4.xml · nonDerivative · entry 3 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 80,000 F2 · ownership.nature: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 9, 2022 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017591 · doc4.xml · nonDerivative · entry 2 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 147,915 F1 · ownership.nature: The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 16:12 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 2,470 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-20-059634 · doc4.xml · derivative · entry 4 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,867 Underlying: Common Stock · 2,470 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported shares are subject to the terms of a lock-up agreement, dated June 23, 2020 (the "Lock-Up Agreement"). This report on Form 4 is in accordance with Section (v) of the Lock-Up Agreement. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 16:12 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 2,470 | $0.53 | $1,309.10 |
DisclosureSEC source: 0001209191-20-059634 · doc4.xml · nonDerivative · entry 1 Mack David Henry · CIK 0001341642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported shares are subject to the terms of a lock-up agreement, dated June 23, 2020 (the "Lock-Up Agreement"). This report on Form 4 is in accordance with Section (v) of the Lock-Up Agreement. Read SEC document |
| May 05, 2020 Filed May 28, 2020 20:01 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011290 · doc1.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 15, 2019 19:02 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001567619-19-011352 · doc1.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 14, 2019, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 16:38 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantInitial Option Grant · Derivative | 40,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001567619-19-005097 · doc1.xml · derivative · entry 1 Mack David Henry · CIK 0001341642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-18 F1 · derivative.exercise_date: The shares subject to the initial option grant vest 1/3 after the first year, the remaining shares will vest quarterly in years two and three following the grant date of February 19, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.